In vivo activity of novel sulphonic derivatives of distamycin A.
Solid tumor growth can be modulated through inhibition of vascularization elicited by angiogenic factors. With the objective to complex these factors, new derivatives of distamycin A were synthesized and evaluated in vitro [1] and in vivo for their ability, after i.v. administration, to inhibit bFGF-induced vascularization and the growth of M5076 murine reticulosarcoma implanted i.m. The tested compounds were able to block angiogenesis with inhibition values ranging between 70-100%. Moreover, they were found to be capable of inducing tumor inhibition with values ranging between 40% and 95% at non-toxic doses.
Sola
F
F
Farmitalia Carlo Erba, Erbamont Group, Research and Development Center, Nerviano, Italy.
Biasoli
G
G
Pesenti
E
E
Farao
M
M
Della Torre
P
P
Mongelli
N
N
Grandi
M
M
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003094:Collagen; D004214:Distamycins / Q000627:therapeutic use*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000517:prevention & control*; D019736:Prostheses and Implants; D013329:Structure-Activity Relationship; D013451:Sulfonic Acids / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004214:Distamycins; D013451:Sulfonic Acids; D016222:Fibroblast Growth Factor 2; C030000:stallimycin; D003094:Collagen